GFT505
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| 2-[2,6 dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)-propenyl]phenoxyl]-2-methylpropanoic acid[1] | |
| Clinical data | |
| Pregnancy cat. | N/A |
| Legal status | Investigational |
| Identifiers | |
| ATC code | None |
| PubChem | CID 9864881 |
| ChemSpider | 8040573 |
| Synonyms | SureCN815512 |
| Chemical data | |
| Formula | C22H24O4S |
| Mol. mass | 384.489 g/mol |
| SMILES
| |
| |
GFT505 is a research drug that is being developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[2][3]
GFT505 is a dual PPARα/δ agonist.[4][5]
See also
References
- ↑ Cariou, B.; Zair, Y.; Staels, B.; Bruckert, E. (2011). "Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients with Combined Dyslipidemia or Impaired Glucose Metabolism". Diabetes Care 34 (9): 2008–2014. doi:10.2337/dc11-0093. PMC 3161281. PMID 21816979.
- ↑ "Advanced Compound Status" (Press release). Genfit.
- ↑ "GFT505 Broadens Its Therapeutic Potential" (Press release). Retrieved 31 Mar 2013.
- ↑ US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641". Retrieved 31 Mar 2013.
- ↑ "GFT-505". Drugs of the Future 37 (8): 555–559. 2012.
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.